Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The Offers expired at 5:00 p.m.,
At the Expiration Date, according to information provided by D.F. King & Co., Inc., the tender and information agent for the Offers (the “Tender and Information Agent”), the aggregate principal amount of each Series of Notes validly tendered and not validly withdrawn pursuant to the Offers and the aggregate principal amount of each Series of Notes accepted for purchase are set forth in the table below.
Series of Notes |
CUSIP/ISIN Number (1) |
Aggregate Principal Amount Outstanding Prior to Tender Offer |
Series Cap |
Acceptance Priority Level |
Total Consideration(2) |
Aggregate Principal Amount Tendered |
Aggregate Principal Amount Accepted |
|||||||
|
444859BR2 / US444859BR26 |
|
N/A |
1 |
|
|
|
|||||||
|
444859BK7 / US444859BK72 |
|
N/A |
2 |
|
|
|
|||||||
|
444859BT8 / US444859BT81 |
|
N/A |
3 |
|
|
|
|||||||
|
444859BN1 / US444859BN12 |
|
N/A |
4 |
|
|
|
|||||||
|
444859BQ4 / US444859BQ43 |
|
N/A |
5 |
|
|
|
|||||||
|
444859BF8 / US444859BF87 |
|
N/A |
6 |
|
|
|
|||||||
|
444859CA8 / US444859CA81 |
|
|
7 |
|
|
|
|||||||
|
444859BU5 / US444859BU54 |
|
N/A |
8 |
|
|
— |
(1) |
No representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers listed above. |
(2) |
Represents the total consideration for each Series of Notes (the “Total Consideration”) payable per each |
All conditions to the Offers were satisfied or waived on or prior to the Expiration Date. On the “Settlement Date” of November 18, 2026, Holders whose Notes have been accepted for purchase will also receive an Accrued Coupon Payment. The Notes validly tendered but not accepted for purchase will be returned promptly to the tendering Holders in accordance with the Offer to Purchase.
Based upon information received from the Tender and Information Agent, Humana will accept all tendered February 2032 Notes, August 2029 Notes, March 2029 Notes, April 2030 Notes, February 2027 Notes and March 2027 Notes in full, and will accept the April 2031 Notes at a proration factor of approximately
Barclays Capital Inc., BofA Securities, Inc., PNC Capital Markets LLC and
This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The Offers were made only by and pursuant to the terms of the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. The information in this press release is qualified by reference to the Offer to Purchase.
Humana Cautionary Statement
Some of the information included in this press release and the Offer to Purchase may include both historical and forward-looking statements. When used in this press release or the Offer to Purchase (and any documents that we incorporate by reference in the Offer to Purchase), the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events, trends and uncertainties. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including information set forth under “Risk Factors” beginning on page 17 of the Offer to Purchase, matters described in the Offer to Purchase and in the documents incorporated by reference in the Offer to Purchase, including the “Risk Factors” contained in certain documents incorporated by reference in the Offer to Purchase.
Forward-looking statements should be read in conjunction with the other cautionary statements, risks, uncertainties and other factors identified in our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequently filed reports with the U.S. Securities and Exchange Commission and elsewhere in the Offer to Purchase. You should read the Offer to Purchase completely and with the understanding that actual future results may be materially different from expectations. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release and the Offer to Purchase (and any documents that we incorporate by reference in the Offer to Purchase) might not occur. Our business is highly complicated, regulated and competitive with many different factors affecting results. There may also be other risks that we are unable to predict at this time.
About Humana
Humana Inc. is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116970634/en/
Investors: Lisa Stoner - Humana Investor Relations; (502) 580-2652; lstamper@humana.com
Media: Mark Taylor - Humana Corporate Communications; (317) 753-0345; MTaylor108@humana.com
Source: Humana Inc.